News about "inflammatory bowel disease "

Duvakitug Shows Durable Efficacy in Ulcerative Colitis and Crohn's Disease in Long-Term Study

Duvakitug Shows Durable Efficacy in Ulcerative Colitis and Crohn's Disease in Long-Term Study

Long-term extension data show sustained remission and endoscopic response with duvakitug in ulcerative colitis and Crohn’s disease, strengthening its position as a potential next-generation TL1A therapy.

Inflammatory Bowel Disease | 18/02/2026 | By News Bureau

WuXi Biologics, Sinorda Biomedicine Partner to Advance Bispecific Antibody for Autoimmune Diseases

WuXi Biologics, Sinorda Biomedicine Partner to Advance Bispecific Antibody for Autoimmune Diseases

WuXi Biologics and Sinorda Biomedicine collaborate to accelerate development of SND006, a novel bispecific antibody targeting inflammatory bowel disease and autoimmune disorders.

Inflammatory Bowel Disease | 29/01/2026 | By News Bureau

AbbVie to Acquire Nimble Therapeutics to Expand its Immunology Pipeline

AbbVie to Acquire Nimble Therapeutics to Expand its Immunology Pipeline

AbbVie will acquire Nimble's peptide synthesis, screening, and optimization platform, which uses proprietary technology to help drive rapid discovery and optimization of peptide candidates for a range of targets.

Inflammatory Bowel Disease | 18/12/2024 | By Aishwarya 659

Lilly to Acquire Morphic to Enhance Outcomes for Patients with IBD

Lilly to Acquire Morphic to Enhance Outcomes for Patients with IBD

Eli Lilly and Company has signed a definitive agreement to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for the treatment of serious chronic diseases.

Inflammatory Bowel Disease | 09/07/2024 | By Aishwarya 729

Johnson & Johnson Submits Application to US FDA Seeking Approval of TREMFYA

Johnson & Johnson Submits Application to US FDA Seeking Approval of TREMFYA

Johnson & Johnson has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) seeking approval of TREMFYA (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease.

Inflammatory Bowel Disease | 21/06/2024 | By Aishwarya 501


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members